Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:Philip_Morris_International
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:focus |
asthma
chronic obstructive pulmonary disease respiratory diseases |
| gptkbp:founded |
1997
|
| gptkbp:founder |
David Gawkrodger
|
| gptkbp:headquartersLocation |
Chippenham, England
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vectura Group
|
| gptkbp:industry |
pharmaceuticals
inhaled drug delivery |
| gptkbp:numberOfEmployees |
~400 (2021)
|
| gptkbp:parentCompany |
gptkb:Philip_Morris_International
|
| gptkbp:product |
inhalers
dry powder inhalers nebulisers |
| gptkbp:stockExchange |
gptkb:London_Stock_Exchange
|
| gptkbp:stockSymbol |
VEC
|
| gptkbp:website |
https://www.vectura.com/
|
| gptkbp:bfsParent |
gptkb:Philip_Morris_International
|
| gptkbp:bfsLayer |
6
|